David Kallend
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 18
- Surgery top 0.2%
- Lipoproteins and Cardiovascular Health 72
- Cholesterol and Lipid Metabolism 8
- Cancer Research top 1%
- Cancer, Lipids, and Metabolism 16
- Economics and Econometrics top 0.5%
- Pharmaceutical Economics and Policy 15
- Health Systems, Economic Evaluations, Quality of Life 11
-
- Cardiac Imaging and Diagnostics 10
-
- Computational Drug Discovery Methods 9
- Co-authors
- Lawrence A. LeiterR. Scott WrightPeter WijngaardJohn J.P. KasteleinKausik K. RayWolfgang KöenigFrederick J. RaalMark Jaros
- Journals
- Atherosclerosis (11 papers)Journal of the American College of Cardiology (10 papers)European Heart Journal (8 papers)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
David Kallend
94 papers receiving 7.6k citations
Hit Papers
Peers
Comparison fields: 5 of 117
- Endocrinology, Diabetes and Metabolism 2.6k
- Surgery 5.4k
- Cancer Research 1.5k
- Cardiology and Cardiovascular Medicine 1.8k
- Economics and Econometrics 1.2k
Countries citing papers authored by David Kallend
This map shows the geographic impact of David Kallend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kallend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kallend more than expected).
Fields of papers citing papers by David Kallend
This network shows the impact of papers produced by David Kallend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kallend. The network helps show where David Kallend may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David Kallend, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 6 | |
| 3 | 2024 | 2 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 2 | |
| 8 | Inclisiran and cardiovascular events: a patient-level analysis of phase III trialsbreakdown → | 2022 | 131 |
| 9 | 2020 | 16 | |
| 10 | 2020 | 4 | |
| 11 | 2020 | 3 | |
| 12 | 2020 | 3 | |
| 13 | 2016 | 25 | |
| 14 | 2016 | 43 | |
| 15 | 2015 | 192 | |
| 16 | 2015 | 62 | |
| 17 | 2013 | 57 | |
| 18 | 2012 | 5 | |
| 19 | 2010 | 1 | |
| 20 | 2004 | 134 |
About David Kallend
David Kallend is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research, having authored 99 papers that have together received 7.8k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (72 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (18 papers), Cancer, Lipids, and Metabolism (16 papers), Pharmaceutical Economics and Policy (15 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers), Cardiac Imaging and Diagnostics (10 papers), Computational Drug Discovery Methods (9 papers) and Cholesterol and Lipid Metabolism (8 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (2.6k citations), Surgery (5.4k citations) and Cancer Research (1.5k citations). David Kallend has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Lawrence A. Leiter, R. Scott Wright, Peter Wijngaard, John J.P. Kastelein, Kausik K. Ray, Wolfgang Köenig, Frederick J. Raal, Mark Jaros, Gregory G. Schwartz and Markus Abt. Their work appears in journals such as Atherosclerosis, Journal of the American College of Cardiology, European Heart Journal, Circulation and Atherosclerosis Supplements.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.